Yawn Barbara P, Saddier Patricia, Wollan Peter C, St Sauver Jennifer L, Kurland Marge J, Sy Lina S
Department of Research, Olmsted Medical Center, 210 Ninth St SE, Rochester, MN, USA.
Mayo Clin Proc. 2007 Nov;82(11):1341-9. doi: 10.4065/82.11.1341.
To establish accurate, up-to-date, baseline epidemiological data for herpes zoster (HZ) before the introduction of the recently licensed HZ vaccine.
Using data from January 1, 1996, to October 15, 2005, we conducted a population-based study of adult residents (Greater than or equal to 22 years) of Olmsted County, MN, to determine (by medical record review) the incidence of HZ and the rate of HZ-related complications. Incidence rates were determined by age and sex and adjusted to the US population.
A total of 1669 adult residents with a confirmed diagnosis of HZ were identified between January 1, 1996, and December 31, 2001. Most (92%) of these patients were immunocompetent and 60% were women. When adjusted to the US adult population, the incidence of HZ was 3.6 per 1000 person-years (95% confidence interval, 3.4-3.7), with a temporal increase from 3.2 to 4.1 per 1000 person-years from 1996 to 2001. The incidence of HZ and the rate of HZ-associated complications increased with age, with 68% of cases occurring in those aged 50 years and older. Postherpetic neuralgia occurred in 18% of adult patients with HZ and in 33% of those aged 79 years and older. Overall, 10% of all patients with HZ experienced 1 or more nonpain complications.
Our population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.
在最近获批的带状疱疹(HZ)疫苗引入之前,建立准确、最新的HZ基线流行病学数据。
利用1996年1月1日至2005年10月15日的数据,我们对明尼苏达州奥尔姆斯特德县的成年居民(年龄大于或等于22岁)进行了一项基于人群的研究,以确定(通过病历审查)HZ的发病率和HZ相关并发症的发生率。发病率按年龄和性别确定,并根据美国人口进行调整。
在1996年1月1日至2001年12月31日期间,共确定了1669例确诊为HZ的成年居民。这些患者中大多数(92%)免疫功能正常,60%为女性。根据美国成年人口调整后,HZ的发病率为每1000人年3.6例(95%置信区间,3.4 - 3.7),从1996年到2001年,发病率从每1000人年3.2例暂时增加到4.1例。HZ的发病率和HZ相关并发症的发生率随年龄增加,68%的病例发生在50岁及以上人群中。带状疱疹后神经痛发生在18%的成年HZ患者中,在79岁及以上患者中为33%。总体而言,所有HZ患者中有10%经历了1种或更多种非疼痛性并发症。
我们基于人群的数据表明,HZ主要影响50岁以上免疫功能正常的成年人;四分之一的患者会经历某种类型的HZ相关并发症。